Titlebook: Antifungal Agents; Advances and Problem Johannes Müller,Annemarie Polak,Kathrin Tintelnot, Book 2003 Birkh?user Verlag 2003 chemotherapy.di

債務(wù)人

書目名稱Antifungal Agents影響因子(影響力)




書目名稱Antifungal Agents影響因子(影響力)學(xué)科排名




書目名稱Antifungal Agents網(wǎng)絡(luò)公開度




書目名稱Antifungal Agents網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Antifungal Agents被引頻次




書目名稱Antifungal Agents被引頻次學(xué)科排名




書目名稱Antifungal Agents年度引用




書目名稱Antifungal Agents年度引用學(xué)科排名




書目名稱Antifungal Agents讀者反饋




書目名稱Antifungal Agents讀者反饋學(xué)科排名

ornithology

Book 2003irst chapter gives an account of the various growth forms of pathogenic fungi and classifies them based on their sexual cycle and on their RNA/DNA patterns. The second chapter describes the clinical manifestations of human fungal infections, their prevalence and epidemiology. The third chapter is de

Carcinogen

0071-786X L COMPOUNDS COVERAGE OF DIAGNOSIS AND SUSCEPTIBILITY.IncludeThis second volume of PDR SPECIAL TOPICS contains five review articles dealing with fungal diseases in humans as well as therapeutic approaches. The first chapter gives an account of the various growth forms of pathogenic fungi and classifi

Anthrp

1.4.2 General features of the data,presentation follows the order of prevalence and overall importance of the fungal infections. Short paragraphs on the ecology of the causative fungi and the epidemiology of the corresponding diseases, including the mode of aquisition, the susceptible population, and the geographical distribution, precede each clinical entity.

預(yù)知

產(chǎn)生

羞辱

Diagnosis of fungal diseases,etection, DNA detection, and antibody detection, is concisely described. Identification techniques depend on the fungal group involved. Therefore, separate paragraphs are dedicated to the identification of yeasts and filamentous fungi, which include moulds, dermatophytes, and dimorphic fungi.

POWER

1.4.2 General features of the data,ant place in the treatment of severely compromised patients, and the field of prevention and empiric therapy is fast moving. Guidelines exist nowadays for the treatment of various fungal diseases and maintenance therapy. New approaches interfering with host defenses or pathogenicity of fungal cells

ASSAY

1.4.2 General features of the data,rediction of MICs on the clinical outcome is discussed. Since there are some pitfalls in testing antifungals, this should be done in experienced laboratories only. The MIC has to be regarded as only one, but an important, factor in the management of fungal diseases. Host-, drug-, and pathogen-specif

彈藥